Fol. Biol. 2022, 68, 153-157

https://doi.org/10.14712/fb2022068040153

Circulating Cell-Free DNA Extraction from Liquid Biopsy for Cancer Research

L. Pfeiferova1, M. Safarikova1, J. Ulrych2, Z. Krska2, V. Frankova3, T. Zima1, Marta Kalousová1

1Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
21st Department of Surgery – Department of Abdominal, Thoracic Surgery and Traumatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
3Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic

Received October 2022
Accepted December 2022

References

1. Addeo, A., Weiss, G. J. (2019) Measuring tumor mutation burden in cell-free DNA: advantages and limits. Transl. Lung Cancer Res. 8, 553-555. <https://doi.org/10.21037/tlcr.2019.03.04>
2. Gedvilaitė, V., Schveigert, D., Cicėnas, S. (2017) Cell-free DNA in non-small cell lung cancer. Acta Med. Litu. 24, 138-144.
3. Ghosh, R. K., Pandey, T., Dey, P. (2019) Liquid biopsy: a new avenue in pathology. Cytopathology 30, 138-143. <https://doi.org/10.1111/cyt.12661>
4. Johann, D. J. Jr., Steliga, M., Shin, I. J., Yoon, D., Arnaoutakis, K., Hutchins, L., Liu, M., Liem, J., Walker, K., Pereira, A., Yang, M. (2018) Liquid biopsy and its role in an advanced clinical trial for lung cancer. Exp. Biol. Med. 243, 262-271. <https://doi.org/10.1177/1535370217750087>
5. Kilgour, E., Rothwell, D. G., Brady, G., Dive, C. (2020) Liquid biopsy-based biomarkers of treatment response and resistance. Cancer Cell 37, 485-495. <https://doi.org/10.1016/j.ccell.2020.03.012>
6. Kustanovich, A., Schwartz, R., Peretz, T., Grinshpun, A. (2019) Life and death of circulating cell-free DNA. Cancer Biol. Ther. 20, 1057-1067. <https://doi.org/10.1080/15384047.2019.1598759>
7. Lee, J., Kim, M., Seong, M., Kim, H., Lee, Y., Kang, H. (2020) Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction. Clin. Chem. Lab. Med. 58, 527-532. <https://doi.org/10.1515/cclm-2019-0896>
8. Michela, B. (2021) Liquid biopsy: a family of possible diagnostic tools. Diagnostics (Basel) 11, 1391. <https://doi.org/10.3390/diagnostics11081391>
9. Normanno, N., Denis, M. G., Thress, K. S., Ratcliffe, M., Reck, M. (2017) Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. Oncotarget 8, 12501-12516. <https://doi.org/10.18632/oncotarget.13915>
10. Pessoa, L. S., Heringer M., Ferrer, V. P. (2020) ctDNA as a cancer biomarker: a broad overview. Crit. Rev. Oncol. Hematol. 155, 103109. <https://doi.org/10.1016/j.critrevonc.2020.103109>
11. Pittella-Silva, F., Chin, Y. M., Chan, H. T., Nagayama, S., Miyauchi, E., Low, S. K., Nakamura, Y. (2020) Plasma or serum: which is preferable for mutation detection in liquid biopsy? Clin. Chem. 66, 946-957. <https://doi.org/10.1093/clinchem/hvaa103>
12. Taback, B., O’Day, S. J., Hoon, D. S. (2004) Quantification of circulating DNA in the plasma and serum of cancer patients. Ann. N. Y. Acad. Sci. 1022, 17-24. <https://doi.org/10.1196/annals.1318.004>
13. Umetani, N., Hiramatsu, S., Hoon, D. S. (2006) Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. Ann. N. Y. Acad. Sci. 1075, 299-307. <https://doi.org/10.1196/annals.1368.040>
14. Yeo, J. C., Lim, C. T. (2018) Potential of circulating biomarkers in liquid biopsy diagnostics. Biotechniques 65, 187-189. <https://doi.org/10.2144/btn-2018-0093>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Archive